
Releases
Capricor Therapeutics Investors Face Lead Plaintiff Deadline
Investors who incurred financial losses holding Capricor Therapeutics stock now have until September 28, 2026, to file as lead plaintiffs in a pending securities fraud class action. The litigation centers on allegations that the company obscured critical regulatory hurdles regarding its Duchenne muscular dystrophy treatment, Deramiocel.


























